274 completed, 61 unknown, 33 terminated, 16 recruiting. 402 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 402 | Completed 274, Unknown 61, Terminated 33, Recruiting 16, Withdrawn 8, Not yet recruiting 7, Active not recruiting 2, Enrolling by invitation 1 |
Follow Hyperinsulinism: new trials by email Literature Review of Hyperinsulinism trials Research Report on Hyperinsulinism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing Trauma-related Links Between Affective and Metabolic Systems prazosin - Posttraumatic Stress Disorder, Metabolic Syndrome | Phase 4 | Not yet recruiting | VA Office of Research and Development | 70 | 2027-03-01 | 2026-10-15 |
| Metabolic Surgery for Atrial Fibrillation Elimination Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment - Atrial Fibrillation, Obesity and Obesity-related Medical Conditions | Phase 4 | Not yet recruiting | Ali Aminian | 100 | 2026-11-01 | 2026-04-17 |
| Mazdutide for Weight Management and Gout in Adults With Obesity Mazdutide - Gout, Obesity (BMI>30) | Phase 4 | Not yet recruiting | Hongwei Jiang | 30 | 2026-09-15 | 2026-09-17 |
| Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. Tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.) - Obesity, Diabetes Mellitus, Type 2 | Phase 4 | Recruiting | Las Rías Medical Center | 160 | 2026-07-27 | 2026-05-19 |
| Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance Metyrapone And Hydrocortisone, Dextrose, insulin - Shift Work Schedule, Circadian Rhythm | Phase 4 | Recruiting | Washington State University | 48 | 2026-07-16 | 2026-09-18 |
| Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE) Mazdutide, Placebo, Standardized Lifestyle Intervention - Prediabetes, Impaired Fasting Glucose | Phase 4 | Not yet recruiting | Shandong Provincial Hospital | 150 | 2026-07-01 | 2026-06-17 |
| Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV Tirzepatide - Human Immunodeficiency Virus (HIV), Metabolic Dysfunction Associated Steatotic Liver Disease | Phase 4 | Enrolling by invitation | National Taiwan University Clinical Trial Center | 60 | 2026-06-25 | 2026-07-20 |
| Preoperative Maltodextrin's Effect on Cardiac Function in Cardiac Surgery Maltodextrin solution, Placebo solution - Left Ventricular Dysfunction, Quality of Recovery | Phase 4 | Not yet recruiting | Jewish General Hospital | 70 | 2025-12-01 | 2025-02-24 |
| Continuous Glucose Monitoring By DExcom iN PEople Followed for Type 2 DIabeTes on Insulin Therapy in the Kingdom of Saudi Arabia Real-Time Continuous Glucose Monitoring - Type 2 Diabetes on Insulin | Phase 4 | Active not recruiting | DexCom, Inc. | 200 | 2025-11-24 | 2026-05-22 |
| Vericiguat and Reverse Remodeling Indices in Heart Failure Vericiguat, Guideline Directed Medical Therapy for Heart Failure (GDMT) - Heart Failure With Reduced Ejection Fraction (HFrEF), Chronic Heart Failure | Phase 4 | Recruiting | University Medical Centre Ljubljana | 70 | 2025-11-01 | 2026-09-29 |
| Efficacy of NOSHINtrial in Diabetic Patients anti-diabetic herbal drug - Diabetes Mellitus, Type 2, Insulin Resistance | Phase 4 | Completed | Kerman Medical University | 70 | 2025-09-26 | 2026-08-10 |
| Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors Sitagliptin 100 mg, Sitagliptin 100 mg + Dapagliflozin 10 mg, Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg - Diabetes Mellitus, Type 2, Hyperglycemia | Phase 4 | Not yet recruiting | Yonsei University | 100 | 2025-09-01 | 2025-08-07 |
| Metformin Effects on Metabolic, Vitamin B12, Iron, Erythropoietin, and Hematological Parameters in Women With PCOS Metformin, Matching Placebo - Polycystic Ovary Syndrome (PCOS) Women | Phase 4 | Completed | Jerash Private University | 400 | 2025-08-01 | 2026-08-31 |
| Association Between Diastolic Dysfunction and Erectile Dysfunction and the Effect of Tadalafil and SGLT2 Inhibitors on Them in Men With Metabolic Syndrome Tadalafil 5 mg, SGLT-2 inhibitor, Tadalafil plus SGLT2 inhibitors - Erectile Dysfunction, Left Ventricular Diastolic Dysfunction | Phase 4 | Completed | Kafrelsheikh University | 60 | 2025-05-05 | 2026-05-04 |
| Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota. Vonoprazan-Amoxicillin Dual Therapy, Vonoprazan-Amoxicillin with Bifidobacterium tetravaccae, Vonoprazan-Amoxicillin with Berberine - HELICOBACTER PYLORI INFECTIONS, Metabolic Syndrome | Phase 4 | Recruiting | Nanjing First Hospital, Nanjing Medical University | 120 | 2025-04-17 | 2026-04-13 |
| Topical Insulin for Ocular Surface Interface in Dry Eye Disease Artificial tear, insulin human - Dry Eye, Insulin Sensitivity | Phase 4 | Completed | Khyber Teaching Hospital | 128 | 2025-04-14 | 2026-08-14 |
| LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL - Drug Interactions, Primary Prevention | Phase 4 | Recruiting | University of California, San Diego | 100 | 2025-04-02 | 2026-11-10 |
| Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience DTG/3TC, Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF) - HIV Infection, Metabolic Syndrome | Phase 4 | Recruiting | Instituto Mexicano del Seguro Social | 124 | 2025-04-01 | 2025-06-26 |
| Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide Insulin resistance testing, OGTT, Fat biopsy - Diabetes Mellitus, Type 2, Diabetes | Phase 4 | Recruiting | Stanford University | 104 | 2025-01-13 | 2026-04-20 |
| Effects of D-Chiro-Inositol Combined with Metformin on Insulin Resistance in People with Overweight or Obesity and T2DM D-Chiro-Inositol Combined with Metformin, Placebo in combination with metformin - Type 2 Diabetes, Overweight and Obese Adults | Phase 4 | Active not recruiting | Campus Bio-Medico University | 16 | 2025-01-10 | 2025-03-11 |
Showing 20 of 402. Sign in to see all of them.
Insulin Resistance (285) · Metabolic Syndrome (139) · Diabetes Mellitus, Type 2 (88) · Diabetes Mellitus (73) · Obesity (49) · Hypertension (33) · Schizophrenia (22) · Inflammation (18) · Glucose Intolerance (17) · Hyperglycemia (16) · Cardiovascular Diseases (15) · Diabetes Mellitus, Type 1 (14) · Polycystic Ovary Syndrome (13) · Prediabetic State (12) · Hypogonadism (11)
Nutritional and Metabolic Diseases (402) · Glucose Metabolism Disorders (399) · Metabolic Diseases (398) · Endocrine System Diseases (175) · Insulin Resistance (114) · Pathological Conditions, Signs and Symptoms (107) · Diabetes Mellitus (80) · Signs and Symptoms (77) · Body Weight (63) · Nutrition Disorders (62) · Cardiovascular Diseases (61) · Overnutrition (60) · Vascular Diseases (51) · Overweight (50)
Metformin (55) · Insulin (41) · Insulin Glargine (29) · Pioglitazone (24) · Insulin Aspart (14) · Liraglutide (11) · Aripiprazole (10) · Insulin Lispro (10) · Rosiglitazone (10) · Hydrochlorothiazide (9) · Losartan (7) · Sitagliptin Phosphate (7) · Testosterone (7) · Ezetimibe, Simvastatin Drug Combination (6) · Fenofibrate (6)
Gachon University Gil Medical Center (11) · Novartis (7) · AstraZeneca (5) · Eli Lilly and Company (4) · Massachusetts General Hospital (4) · Seoul National University Hospital (4) · Stanford University (4) · Tanabe Pharma Corporation (4) · Tottori University Hospital (4) · University Medical Centre Ljubljana (4) · University of Texas Southwestern Medical Center (4) · German Diabetes Center (3) · Gulhane School of Medicine (3) · Mannkind Corporation (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3)
United States (127) · South Korea (30) · Italy (19) · Canada (18) · China (17) · Denmark (15) · Germany (15) · Netherlands (12) · India (9) · Japan (9) · Taiwan (9) · France (8) · Mexico (8) · Spain (8) · Turkey (Türkiye) (8)
Kazuoki Kondo, MD (4) · David C Henderson, MD (3) · Kevin Kaiserman, MD (3) · Tania S Burgert, MD (3) · Frank LJ Visseren, MD PhD (2) · Gary F. Lewis, MD (2) · Hildo J Lamb, MD PhD (2) · Ingrid M Jazet, MD PhD (2) · Jonathan M. Meyer, MD (2) · Jothydev Kesavadev, MD (2) · Kazuhide Ogino, MD (2) · Lidia S Szczepaniak, PhD (2) · Mark E Molitch, M.D. (2)
PMID 22773702, PMID 24445038, PMID 33293204, PMID 36262060, PMID 37526194, PMID 39641307, PMID 39963952, PMID 10332663, PMID 10480510, PMID 10857969, PMID 10950834, PMID 15482620, PMID 1574446, PMID 1578097, PMID 16842478, PMID 16988754, PMID 17130190, PMID 17229660, PMID 17259511, PMID 17305652, PMID 17327353, PMID 17539698, PMID 17683100, PMID 17850473, PMID 18172212, PMID 18394022, PMID 18413332, PMID 18544618, PMID 18647805, PMID 18670365, PMID 18761646, PMID 18824462, PMID 19053049, PMID 19104769, PMID 19120715, PMID 19125756, PMID 19263591, PMID 19394149, PMID 19546056, PMID 19689921, PMID 19698065, PMID 19732305, PMID 19755697, PMID 19814947, PMID 19885233, PMID 19933411, PMID 20022616, PMID 20026785, PMID 20059570, PMID 20101593
2005 (3), 2016 (3), 2008 (2), 2014 (2), 2015 (1), 2019 (1), K01MH095920 (1), K12HD057022 (1), K23AT002862 (1), K23DK068223 (1), K23DK074439 (1), K23DK079789 (1), K23HD092893 (1), K23HL086558 (1), K23MH074540 (1)